During the past decade, Suburban Hematology-Oncology Associates conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 11 clinical trials were completed, i.e. on average, 550% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Suburban Hematology-Oncology Associates" #1 sponsor was "Novartis Pharmaceuticals" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Telik" with 3 trials sponsored, "Translational Oncology Research International" with 3 trials sponsored and "NSABP Foundation Inc" with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Suburban Hematology-Oncology Associates" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Cancer International Research Group (CIRG)" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Suburban Hematology-Oncology Associates" are "Breast Cancer" (11 trials), "Colorectal Cancer" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Non-Small Cell Lung Cancer" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Suburban Hematology-Oncology Associates" in a lesser frequency.

Most popular intervention types in "Suburban Hematology-Oncology Associates" are "Drug" (30 trials), "Other" (3 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cyclophosphamide" (3 trials), "Docetaxel" (3 trials), "docetaxel" (3 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Suburban Hematology-Oncology Associates" are 16 trials for "All" genders, 12 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Suburban Hematology-Oncology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Suburban Hematology-Oncology Associates, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Suburban Hematology-Oncology Associates, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Suburban Hematology-Oncology Associates has several departments that took part in Clinical trials: "Gwinnett Hospital System Inc. -d/b/a - The Center for Cancer Care" - 2 trials